ClinicalTrials.gg
RecruitingNCT06499480RIAITUpdated Mar 6, 2025

Italian Registry of Allergen ImmunoTherapy

An observational study in Allergic Respiratory Disease, sponsored by Società Italiana di Allergologia, Asma e Immunologia Clinica. Recruiting at 2 sites in Italy. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2025-03-06.

Sponsored by Società Italiana di Allergologia, Asma e Immunologia Clinica · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
1 Year and older
Sex
All
01

Study summary

RIAIT (Italian Registry of Allergy Immunotherapy) is a multicenter observational study that aims to prospectively collect the most extensive data available on Italian patients using AIT for respiratory allergies (rhinoconjunctivitis and/or asthma) in a real-life context, through a network of allergy centers with specific interest and expertise in the management of allergic respiratory patients.

Read the detailed description

Objectives include:

  • Evaluate short and long-term real-life effectiveness and safety of AIT overall, in specific patient groups' phenotypes and with specific AIT products.
  • Evaluate the pertinence and differences in suggesting AIT to a patient comparing physician's evaluation in various settings with established international guidelines, describing the factors associated with treatment choices and changing over time, and promoting interoperability, data sharing, and cross-comparison among centers.
  • Describe long-term respiratory allergic disease evolution in patients treated with AIT.
  • Describe the natural history of the patient population with respiratory allergies and identify patient groups describing their illness burden, management patterns, and clinical progression.
  • Promote the creation of accurate, standardized, and efficient processes for diagnosing and treating respiratory allergic diseases, especially with AIT.
  • Assess biomarker data to predict diagnosis, treatment response and long-term disease progression.
02

Conditions studied

  • Allergic Respiratory Disease
03

In context

Lead sponsor

Società Italiana di Allergologia, Asma e Immunologia Clinica is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

RIAIT is a prospective multicenter observational registry of patients suffering from conjunctivitis, rhinitis, and/or allergic asthma eligible for and treated with AIT according to EAACI (European Academy of Allergy and Clinical Immunology) Guidelines.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 1 year
  • Confirmed diagnosis of allergic rhinoconjunctivitis and/or allergic asthma according to EAACI 2019 guidelines.
  • Having been followed by the recruiting center for at least one month: this is considered necessary to establish that the patients are truly affected by allergic respiratory disease and are eligible for allergen-specific immunotherapy; in this period, screening tests are carried out to exclude and/or confirm concomitant diseases (comorbidities). In fact, according to the aforementioned EAACI guidelines, a patient can be defined as truly eligible for allergen-specific immunotherapy only after a preliminary phase in which the patient is treated with symptomatic therapy; this observation period allows a correct evaluation of the real adherence and response to therapy, as well as the identification and appropriate treatment of any comorbidity and the possible elimination of aggravating factors.
  • Having received the prescription of any of the available AIT products in Italy, irrespectively of the selected allergens and the administration route and schedule.

Exclusion criteria

Exclusion Criteria:

There will no be exclusion criteria, in order to allow a real-life vision of the characteristics of these patients eligible for or treated with allergen-specific immunotherapy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Life Quality as measured by Standardised Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)) (≥12years)

    Time frame: Every year to ten year

  2. Life Quality as measured by Paediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) For Children 6 - 12 years

    Time frame: Every year to ten year

07

Study locations

2 of 2 sites recruiting
  • Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy
    Rozzano, Milano 20089, Italy
    Recruiting
    • Enrico Marco Heffler, MD, PhD · Principal investigator
  • Azienda Ospedaliera Universitaria Istituto di Ricovero e Cura a Carattere Scientifico
    Florence, Italy
    Recruiting
    • Mattia Giovannini, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Dec 2035, 139 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2024
First posted
Jul 12, 2024
StartActual
May 1, 2024
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2035
Last update
Mar 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06499480
Lead sponsor
Società Italiana di Allergologia, Asma e Immunologia Clinica
Collaborators
Società Italiana di Allergologia e Immunologia Pediatrica (SIAIP)
Responsible party
Sponsor
First posted
Jul 12, 2024
Start date
May 1, 2024
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Mar 6, 2025

Study contacts

Enrico Marco Heffler, MD, PhD
Contact
enrico.heffler@hunimed.eu
+39 0282241
Enrico Marco Heffler, MD, PhD
principal investigator · Humanitas Research Hospital IRCCS, Rozzano-Milan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Società Italiana di Allergologia, Asma e Immunologia Clinica

Start the discussion